Century Therapeutics appoints Dr. Murphy and Dr. Lee to Board, expanding from six to eight members

Century Therapeutics, Inc.

Board expanded from six to eight directors; Dr. Murphy (Class III, term to 2027) and Dr. Lee (Class II, term to 2026) appointed.
Dr. Murphy brings life science investment experience; Dr. Lee brings corporate development and CFO background from biotech firms.
Each new director received an initial option grant of 88,000 shares vesting over 36 months and a $40,000 annual cash retainer.
Dr. Murphy joins Compensation and Nominating/Governance Committees; Dr. Lee joins Audit and Compensation Committees.
Appointments effective December 9, 2025; both deemed independent under Nasdaq rules.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.